The MODEL-AD consortium consisting of a Center at Indiana University School of Medicine, The Jackson Laboratory, Sage Bionetworks and the University of Pittsburgh School of Medicine, and a Center at the University of California Irvine has been established by the National Institute on Aging.


Goals of the MODEL-AD Consortium are:

  • Develop the next generation of in vivo AD models based on human data
  • Institute a standardized and rigorous process for characterization of animal models
  • Align the pathophysiological features of AD models with corresponding stages of clinical disease using translatable biomarkers
  • Establish guidelines for rigorous preclinical testing in animal models
  • Ensure rapid availability of animal models, protocols and validation data to all researchers for preclinical drug development

Screening the Optimal Pharmaceutical for Alzheimer’s Disease (STOP-AD) is a program that offers preclinical screening of compounds through the MODEL-AD Preclinical Testing Core.

The MODEL-AD Consortium is a collaboration of: